Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective Androgen Receptor Modulators (SARMs) have emerged as a promising alternative to traditional anabolic steroids, offering similar benefits with reduced side effects. However, the safety and legality of SARMs vary, making it crucial for enthusiasts to exercise caution when choosing wisely.
PRINCETON, N.J. and HOUSTON, July 15, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel...
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™
CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...
PUNE, India, July 14, 2025 /PRNewswire/ -- According to the latest market analysis published by Credence Research, the global Perfume Ingredient Chemicals Market is...
PUNE, India, July 14, 2025 /PRNewswire/ -- According to the latest market analysis published by Credence Research, the global Perfume Ingredient Chemicals Market is...
Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk.
Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk.
New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) --
For decades, the use of muscle building steroids has been a driving force behind the pursuit of muscle growth and physical prowess among bodybuilders, athletes, and sports professionals.
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...
LONDON, July 4, 2025 /PRNewswire/ -- Star Technical Solutions' Managing Director, Dr Dermot Cotter CEng FInstR, will lead a key ASHRAE webinar on Friday 4th...